Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Repolarization in Healthy Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2012 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

NCT05841160
View directory record Official record
Conditions
QT/QTc
Interventions
Ecopipam Hydrochloride, Moxifloxacin, Placebo
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects

NCT00434395
View directory record Official record
Conditions
Healthy
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

NCT04795479
View directory record Official record
Conditions
Healthy
Interventions
Relacorilant, Placebo to relacorilant, Moxifloxacin
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

NCT07422298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

NCT05478278
View directory record Official record
Conditions
QTc Interval, Pharmacokinetics
Interventions
Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

NCT06161220
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

4-way Crossover QT Evaluation in Healthy Subjects

NCT03709927
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
ZTI-01, Moxifloxacin 400mg, Placebo IV
Drug · Other
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)

NCT00914121
View directory record Official record
Conditions
Healthy Subjects
Interventions
SKI-606, Placebo, Moxifloxacin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

NCT03258515
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD6094 200 mg, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

NCT02889367
View directory record Official record
Conditions
Healthy
Interventions
Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

NCT05933447
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl, Moxifloxacin, Placebo for Rodatristat, Placebo for Moxifloxacin
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

NCT07272629
View directory record Official record
Conditions
Cardiac Repolarization, Healthy Volunteers
Interventions
Balinatunfib, Moxifloxacin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults

NCT00850746
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
YM443, Placebo, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

NCT02307864
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

NCT02820311
View directory record Official record
Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208, Moxifloxacin 400 mg
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

NCT01565720
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers
Interventions
Isavuconazole, Placebo, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Cardiac Liability Study of Varegacestat in Healthy Participants

NCT06855264
View directory record Official record
Conditions
Healthy Volunteer
Interventions
varegacestat, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT02206204
View directory record Official record
Conditions
Cardiodynamics, Safety, Tolerability, Pharmacokinetics
Interventions
selexipag, placebo for selexipag, moxifloxacin, moxifloxacin-matching placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 45 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 28, 2026, 9:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

NCT02833831
View directory record Official record
Conditions
Healthy
Interventions
ALS-008176, Placebo, Moxifloxacin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 9:29 PM EDT